Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Active, not recruiting · NCT04013854 · Registry updated 2026-09-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-09-04 | NCT04013854 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Abramson Cancer Center at Penn Medicine | 137 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Abramson Cancer Center, University of Pennsylvania | Philadelphia | United States | 3 |
| Duke Cancer Institute | Durham | United States | 47 |
| Lancaster General Hospital | Lancaster | United States | 4 |